证券代码：002001 证券简称：新和成 公告编号：2023-065 浙江新和成股份有限公司 关于第三期员工持股计划出售完毕暨终止的公告 浙江新和成股份有限公司（以下简称"公司"）于 2020 年 10 月 26 日召开 第八届董事会第三次会议、第八届监事会第二次会议，于 2020 年 11 月 11 日召 开 2020 年第二次临时股东大会，审议通过《浙江新和成股份有限公司第三期员 工持股计划（草案）及其摘要》等员工持股计划相关议案，同意公司实施第三期 员工持股计划。具体内容详见公司于 2020 年 10 月 27 日、2020 年 11 月 12 日在 指定信息披露媒体及巨潮资讯网（http://www.cninfo.com.cn）上刊登的公告。 公司于 2022 年 10 月 31 日召开第八届董事会第十四次会议，审议通过《关 于第三期员工持股计划存续期展期的议案》，同意公司第三期员工持股计划存续 期延长 12 个月，即存续期由 2020 年 11 月 11 日至 2022 年 11 月 10 日调整为 2020 年 11 月 11 日至 2023 年 11 月 10 日，其他内容不做变更。具体内容详见 ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 3,593,667,979.82, a decrease of 2.74% compared to CNY 3,694,978,168.41 in the same period last year[3] - Net profit attributable to shareholders for Q3 2023 was CNY 576,061,979.82, down 22.48% from CNY 743,000,000 in the previous year[3] - The basic earnings per share for Q3 2023 was CNY 0.20, a decline of 23.08% compared to CNY 0.26 in the same period last year[4] - Operating profit for Q3 2023 was CNY 2,507,878,228.28, down 29.3% from CNY 3,551,143,658.19 in the same period last year[20] - The total profit for the third quarter was approximately ¥2.51 billion, a decrease of 29.3% from ¥3.55 billion in the same period last year[22] - The net profit for the third quarter was approximately ¥2.12 billion, down 29.9% from ¥3.02 billion year-over-year[22] - The total comprehensive income for the third quarter was approximately ¥2.15 billion, down from ¥3.06 billion year-over-year[22] - Basic and diluted earnings per share for the third quarter were both ¥0.68, down from ¥0.98 in the same period last year[22] Assets and Liabilities - The company's total assets at the end of Q3 2023 were CNY 38,774,279,496.58, reflecting a 1.32% increase from CNY 38,267,625,155.83 at the beginning of the year[4] - Total assets as of September 30, 2023, amounted to CNY 38,774,279,496.58, an increase from CNY 38,268,063,792.50 at the beginning of the year[19] - The company's total liabilities decreased slightly to CNY 14,466,681,832.00 from CNY 14,605,894,699.41 at the beginning of the year[19] - Current assets decreased to CNY 12,361,191,565.93 from CNY 14,111,200,051.59 at the start of the year, reflecting a decline of 12.36%[18] - Long-term borrowings increased to CNY 6,772,092,279.53 from CNY 5,273,637,508.87, representing a growth of 28.38%[19] Cash Flow - The net cash flow from operating activities was approximately ¥2.63 billion, an increase of 3.9% compared to ¥2.53 billion in the previous year[23] - The cash flow from investing activities resulted in a net outflow of approximately ¥2.87 billion, worsening from a net outflow of ¥1.64 billion in the same period last year[24] - The cash flow from financing activities showed a net outflow of approximately ¥293 million, compared to a net inflow of ¥344 million in the previous year[24] - The company received cash from operating activities totaling approximately ¥12.82 billion, a decrease from ¥13.21 billion year-over-year[23] - The company paid approximately ¥3.14 billion in debt repayment during the financing activities, an increase from ¥2.35 billion in the previous year[24] Investments and Expenses - Research and development expenses for Q3 2023 were CNY 630,879,477.56, up from CNY 600,093,376.48 in Q3 2022, indicating a year-over-year increase of 5.15%[20] - Long-term equity investments increased by 59.75% compared to the beginning of the year, attributed to increased investments in joint ventures[7] - The company experienced a 729.26% increase in asset impairment losses year-on-year, primarily due to market price fluctuations of products[9] - Cash flow from investment activities decreased by 74.84% year-on-year, mainly due to reduced financial management of raised funds and increased fixed asset expenditures[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 116,509, with the top 10 shareholders holding 49.22% of the shares[11] - New and Cheng Holdings Group Co., Ltd. holds 1,521,362,525 shares, accounting for 49.22% of the total shares[11] - The top 10 shareholders include various entities, with the largest being New and Cheng Holdings Group Co., Ltd. and Hong Kong Central Clearing Limited[11] - The fourth employee stock ownership plan purchased 29,528,181 shares, representing 0.9553% of the total share capital, at an average price of approximately 16.2368 RMB per share[13] - The total amount for the stock purchase under the fourth employee stock ownership plan is 479,442,157.08 RMB[13] Corporate Governance - The company completed the election of the ninth board of directors and the ninth supervisory board on September 19, 2023[16] - The company appointed Hu Baifan as chairman and Hu Bochuan as vice chairman of the ninth board of directors[16] Fundraising Activities - As of September 30, 2023, the balance of raised funds is 59,770.48 million RMB, including bank deposits and investment income[15] - The company has utilized 123,683.41 million RMB of the raised funds from January to September 2023, with a cumulative investment of 501,503.20 million RMB[15] - The company’s fundraising project has been verified by Tianjian Accounting Firm, confirming the net amount raised is 486,707.55 million RMB[15]

证券代码：002001 证券简称：新和成 公告编号：2023-064 浙江新和成股份有限公司 特别提示： 浙江新和成股份有限公司（以下简称"公司"）于 2023 年 10 月 26 日接到 公司控股股东新和成控股集团有限公司（以下简称"新和成控股公司"）的通知， 基于对公司未来持续稳定发展的信心以及对公司价值的认可，提升投资者信心， 新和成控股公司计划自通知之日起 6 个月内通过深圳证券交易所交易系统允许 的方式（包括但不限于集中竞价、大宗交易等）增持公司股份，拟增持股份的金 额不低于人民币 2 亿元，不超过人民币 3 亿元。本次增持计划不设价格区间，将 根据公司股票价格波动情况及资本市场整体趋势，逐步实施增持计划。现将相关 增持方案披露如下： 4、新和成控股公司在本次公告前 6 个月内，不存在减持公司股份情况。 一、计划增持主体的基本情况 1、计划增持主体名称：新和成控股集团有限公司 2、本次增持计划实施前，新和成控股公司直接持有公司股份 1,521,362,525 股，占公司总股本的 49.22%。实际控制人及一致行动人胡柏藩先生直接持有公 司股份 13,922,998 股，占公司总股本的 0.45%；一 ...

证券代码：002001 证券简称：新和成 公告编号：2023-061 浙江新和成股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）第九届董事会第二次会议于 2023 年 10 月 20 日以电子邮件方式发出会议通知，于 2023 年 10 月 25 日以现场 结合通讯方式召开。应出席董事 11 名，实际出席董事 11 名，符合《公司法》和 《公司章程》的规定。会议经表决形成决议如下： 一、会议以 11 票同意，0 票反对，0 票弃权审议通过《2023 年第三季度报 告》的议案； 《2023 年第三季度报告》中的财务信息在提交董事会审议前已经公司审计 委员会审议通过；《2023 年第三季度报告》全文详见公司同日在指定信息披露媒 体及巨潮资讯网（http://www.cninfo.com.cn）刊登的公告。 二、会议以 7 票同意，0 票反对，0 票弃权审议通过《关于 2023 年度日常关 联交易预计调整的议案》；关联董事胡柏藩、胡柏剡、石观群、王学闻回避表决， 独立董事就该事项 ...

证券代码：002001 证券简称：新和成 公告编号：2023-063 浙江新和成股份有限公司 关于 2023 年度日常关联交易预计调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）于 2023 年 10 月 25 日召开的 第九届董事会第二次会议审议通过《关于 2023 年度日常关联交易预计调整的议 案》，关联董事胡柏藩、胡柏剡、石观群、王学闻进行了回避表决。根据《深圳 证券交易所股票上市规则》《公司章程》及公司《关联交易决策制度》等有关规 定和审批权限，本次关联交易由公司董事会审议批准，无需提交股东大会审议。 单位：人民币万元 一、调整日常关联交易基本情况 根据公司和关联方实际生产经营情况，为更加准确反映公司与关联方 2023 年度日常关联交易情况，拟对预计金额做出合理调整。因公司新项目建设需要， 公司对关联方浙江德力装备有限公司（以下简称"德力装备"）容器设备需求相 应增加，预计关联采购额度增加 2,400 万元。2023 年度日常关联交易预计总额由 62,972.73 万元调整为 65,372.73 万 ...

浙江新和成股份有限公司九届二次董事会 独立董事相关独立意见 根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所股票上市规 则》等法律法规及《公司章程》的有关规定，作为浙江新和成股份有限公司（以 下简称"公司"）第九届董事会独立董事，我们就公司第九届董事会第二次会议 审议《关于 2023 年度日常关联交易预计调整的议案》相关事项发表独立意见如 下： 1、独立董事事前认可情况 我们认为：公司调整 2023 年度与关联方发生的日常关联交易预计系公司正 常生产经营所需，上述关联交易遵守了客观、公正、公平的交易原则；关联董事 进行回避表决，其决策程序合法、有效；定价原则公允，未发现损害公司和股东 利益的情况，我们对此无异议。 独立董事：季建阳、沈玉平、万峰、王洋 2023 年 10 月 27 日 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《公司 章程》等有关规定，我们作为公司的独立董事，现就第九届董事会第二次会议之 《关于 2023 年度日常关联交易预计调整的议案》，发表事前审查意见： 公司在会议召开前提交了 202 ...

Group 1: Company Performance and Projects - The company's methionine project is currently in a phased trial run, showcasing a strong profit margin maintained by Shandong Amino Acid Company since 2005 [1] - The company has developed a fully autonomous, large-scale, green, and integrated solid methionine production facility, overcoming key foreign technologies since 2017 [1] - The demand for vitamin products is recovering, with expectations for price increases as downstream aquaculture profitability improves [2] Group 2: Strategic Development and Innovation - The company adheres to an innovation-driven development strategy, focusing on "chemicals+" and "biological+" as its main strategic directions [2] - Future growth will stem from integrated, series, and collaborative development strategies, enhancing research and application service capabilities [2] - The company plans to strengthen cost control across production, supply, sales, research, and finance to improve product competitiveness [2] Group 3: Financial Planning and Shareholder Returns - The company will arrange capital expenditure plans based on project investment situations, maintaining a stable profit distribution policy and cash dividend plan to reward shareholders [2] - High capital expenditures and dividends have been consistent in recent years, reflecting the company's commitment to investor trust and support [2]

证券代码：002001 证券简称：新和成 公告编号：2023-060 浙江新和成股份有限公司 关于第四期员工持股计划实施进展暨完成股票购买的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 第四期员工持股计划由公司自行管理，第四期员工持股计划管理委员会成员 李华锋经公司职工代表大会选举为公司职工代表监事，王晓碧经公司2023年第二 次临时股东大会选举为公司非职工代表监事。（具体详见公司于2023年9月20日在 指定信息披露媒体及巨潮资讯网（http://www.cninfo.com.cn）上刊登的公告） 除此之外，公司第四期员工持股计划管理委员会成员均未在公司控股股东或实际 控制人单位担任职务，不为公司5%以上股东、实际控制人、董事、监事、高级管 理人员，与前述主体不存在关联关系。 参与第四期员工持股计划的公司董事、监事、高级管理人员与第四期员工持 股计划存在关联关系。第四期员工持股计划自愿放弃所持股份在公司股东大会的 表决权，公司控股股东不会因借款安排增加可支配的公司股份表决权数量，公司 控股股东、实际控制人、董事、监事、高级管理人员与第四期员工持股计划 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 7,418,514,576.09, a decrease of 9.70% compared to CNY 8,215,039,277.03 in the same period last year[19]. - Net profit attributable to shareholders was CNY 1,483,229,236.96, down 33.00% from CNY 2,213,877,419.25 year-on-year[19]. - The basic earnings per share decreased to CNY 0.48, representing a decline of 33.33% compared to CNY 0.72 in the previous year[19]. - The company's total assets at the end of the reporting period were CNY 37,975,841,342.92, a decrease of 0.76% from CNY 38,267,625,155.83 at the end of the previous year[19]. - The weighted average return on equity was 6.09%, down 3.46 percentage points from 9.55% in the same period last year[19]. - The company reported cash flow from operating activities of CNY 1,235,562,621.93, a slight decrease of 0.55% compared to CNY 1,242,456,738.20 in the previous year[19]. - The company reported a total comprehensive income of CNY 1,533,098,569.11 for the first half of 2023, a decrease of 32.1% from CNY 2,256,239,692.57 in the first half of 2022[173]. - The company reported a net profit for the first half of 2023 of CNY 1,496,374,753.42, down 32.6% from CNY 2,223,867,122.27 in the first half of 2022[172]. Investment and Projects - The company has invested in an 18,000 tons/year liquid methionine project in partnership with Sinopec, which is currently under construction[34]. - The investment project for the annual production of 250,000 tons of methionine has reached 99.03% of the planned investment amount of CNY 486.71 million[71]. - The company signed a joint venture cooperation agreement with Sinopec to invest in a methionine production facility, with a total project investment of approximately RMB 3 billion, and has contributed RMB 233.51 million to the joint venture as of June 30, 2023[138]. Research and Development - R&D investment has consistently exceeded 5% of revenue, fostering innovation and collaboration with renowned research institutions[39]. - Research and development expenses decreased by 5.40% to ¥416,575,391.59, mainly due to a reduction in trial-related expenses[46]. - The company plans to enhance its R&D capabilities and improve processes to strengthen its competitive position in the face of industry competition[79]. Environmental Compliance - The company has implemented various environmental protection policies and standards in compliance with national regulations[96]. - The company reported that it has not exceeded the pollutant discharge limits for various water and air pollutants during the reporting period[97]. - The company has successfully maintained compliance with all environmental standards across its facilities[98]. - The company invested CNY 236.51 million in environmental governance in the first half of 2023 and paid CNY 990,000 in environmental protection tax[106]. Risk Management - The company has acknowledged potential risks in its operations and has outlined corresponding measures to mitigate these risks[4]. - The company has established specific operational procedures for foreign exchange hedging to mitigate exchange rate risks[64]. Corporate Governance - The company did not experience any changes in its board of directors or senior management during the reporting period[86]. - The company has not experienced any termination of the employee stock ownership plan during the reporting period[92]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[114]. Market and Sales Strategy - The company emphasizes a customer-centric sales strategy, establishing long-term partnerships and enhancing brand influence through direct sales and strategic collaborations[32]. - The company aims to expand its market presence and diversify its innovation and supply chains to address macroeconomic risks[78]. Financial Position - Total liabilities increased to CNY 5,715,917,912.55 as of June 30, 2023, compared to CNY 5,530,598,342.62 at the beginning of the year, reflecting a rise of 3.3%[169]. - The total equity attributable to the parent company at the end of the reporting period is CNY 23,676,186,350.67, an increase from CNY 21,895,573,658.03 in the previous year, representing a growth of approximately 8.2%[194]. - The company's total assets reached CNY 15,770,264,168.03, compared to CNY 14,152,470,323.94 in the same period last year, indicating a year-over-year increase of about 11.4%[194].

证券代码：002001 证券简称：新和成 公告编号：2023-047 浙江新和成股份有限公司 独立董事提名人声明与承诺 提名人 浙江新和成股份有限公司董事会 现就提名 季建阳 为浙江新和成 股份有限公司第九届董事会独立董事候选人发表公开声明。被提名人已书面同意 作为浙江新和成股份有限公司第九届董事会独立董事候选人（参见该独立董事候 选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经 历、全部兼职、有无重大失信等不良记录等情况后作出的，本提名人认为被提名 人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则 对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过浙江新和成股份有限公司第八届董事会提名委员会或 者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其他可能 影响独立履职情形的密切关系。 √ 是 □ 否 如否，请详细说明：____________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 √ 是 □ 否 如否，请详细说明：___________ ...